文献速递心力衰竭与心肌病

心力衰竭药物治疗与癌症:通路及临床前/临床证据

Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.
PubMed 文献 · Eur Heart J · 2024-01-01

该综述探讨心力衰竭(HF)患者新发癌症风险增高背景下,指南导向药物治疗(GDMT)及地高辛、利尿剂对癌症的影响。文章汇总临床前机制、观察性研究和随机对照试验的荟萃分析证据,并提出未来研究方向。

要点

  • HF患者新发癌症及癌症相关死亡风险显著高于无HF者。
  • 综述评估GDMT支柱药物、地高辛和利尿剂对癌症发生与结局的影响。
  • 需明确HF患者确诊癌症后GDMT是否及如何调整。

核心结论

  • HF患者新发癌症和癌症相关死亡风险显著高于无HF人群。
  • 综述旨在阐述HF支柱药物、地高辛和利尿剂对癌症的影响,并识别需进一步研究和新治疗策略的领域。

研究设计与样本

  • 综述纳入临床前数据、观察性研究、随机对照试验及荟萃分析证据。

主要发现

  • HF患者新发癌症风险及癌症相关死亡率显著高于无HF者。
  • 综述描述了GDMT药物对癌症的推测作用及临床前机制。
  • 综述汇总了观察性研究和随机对照试验的荟萃分析中GDMT对癌症发病率及癌症相关结局的证据。

临床怎么用

  • 需关注HF患者新发癌症风险及癌症相关死亡风险增高。
  • HF患者确诊癌症时,应考虑GDMT的调整问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart failure (HF) patients have a significantly higher risk of new-onset cancer and cancer-associated mortality, compared to subjects free of HF. While both the prevention and treatment of new-onset HF in patients with cancer have been investigated extensively, less is known about the prevention and treatment of new-onset cancer in patients with HF, and whether and how guideline-directed medical therapy (GDMT) for HF should be modified when cancer is diagnosed in HF patients. The purpose of this review is to elaborate and discuss the effects of pillar HF pharmacotherapies, as well as digoxin and diuretics on cancer, and to identify areas for further research and novel therapeutic strategies. To this end, in this review, (i) proposed effects and mechanisms of action of guideline-directed HF drugs on cancer derived from pre-clinical data will be described, (ii) the evidence from both observational studies and randomized controlled trials on the effects of guideline-directed medical therapy on cancer incidence and cancer-related outcomes, as synthetized by meta-analyses will be reviewed, and (iii) considerations for future pre-clinical and clinical investigations will be provided.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Sayour, Paál, Ameri, et al. Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence. Eur Heart J. 2024. PMID: 38441940. doi:10.1093/eurheartj/ehae105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。